Cargando…

Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab

Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory,...

Descripción completa

Detalles Bibliográficos
Autores principales: Keane, Pearse A, Sadda, Srinivas R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130914/
https://www.ncbi.nlm.nih.gov/pubmed/21750610
http://dx.doi.org/10.2147/OPTH.S13774
_version_ 1782207665696407552
author Keane, Pearse A
Sadda, Srinivas R
author_facet Keane, Pearse A
Sadda, Srinivas R
author_sort Keane, Pearse A
collection PubMed
description Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual loss. Fortunately however, the recent introduction of antivascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis(®), Genentech, South San Francisco, CA) and bevacizumab (Avastin(®), Genentech), offers a potentially new treatment approach for clinicians managing this disorder. The results of the BRAVO and CRUISE trials have provided the first definitive evidence for the efficacy and safety of ranibizumab in the treatment of RVO. As a result, ranibizumab has recently been approved by the US Food and Drug Administration for the treatment of RVO-associated macular edema. In this review, we provide a critical evaluation of clinical trial data for the safety and efficacy of ranibizumab, and address unresolved issues in the management of this disorder.
format Online
Article
Text
id pubmed-3130914
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31309142011-07-12 Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab Keane, Pearse A Sadda, Srinivas R Clin Ophthalmol Review Retinal vein occlusions (RVOs) constitute the second most common cause of retinal vascular disease after diabetic retinopathy, with a prevalence of between 1% and 2% in persons older than 40 years of age. Despite the existence of numerous potential therapeutic options, none is entirely satisfactory, and many patients with RVO suffer irreversible visual loss. Fortunately however, the recent introduction of antivascular endothelial growth factor (VEGF) agents, such as ranibizumab (Lucentis(®), Genentech, South San Francisco, CA) and bevacizumab (Avastin(®), Genentech), offers a potentially new treatment approach for clinicians managing this disorder. The results of the BRAVO and CRUISE trials have provided the first definitive evidence for the efficacy and safety of ranibizumab in the treatment of RVO. As a result, ranibizumab has recently been approved by the US Food and Drug Administration for the treatment of RVO-associated macular edema. In this review, we provide a critical evaluation of clinical trial data for the safety and efficacy of ranibizumab, and address unresolved issues in the management of this disorder. Dove Medical Press 2011 2011-06-09 /pmc/articles/PMC3130914/ /pubmed/21750610 http://dx.doi.org/10.2147/OPTH.S13774 Text en © 2011 Keane and Sadda, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Keane, Pearse A
Sadda, Srinivas R
Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_full Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_fullStr Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_full_unstemmed Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_short Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
title_sort retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130914/
https://www.ncbi.nlm.nih.gov/pubmed/21750610
http://dx.doi.org/10.2147/OPTH.S13774
work_keys_str_mv AT keanepearsea retinalveinocclusionandmacularedemacriticalevaluationoftheclinicalvalueofranibizumab
AT saddasrinivasr retinalveinocclusionandmacularedemacriticalevaluationoftheclinicalvalueofranibizumab